Anika Therapeutics Inc. · NASDAQ:ANIK
Anika Therapeutics — Q3 2026 Earnings Presentation
16 slides from Anika Therapeutics's earnings presentation, Nov 6, 2026
Slide 1: Q3 2026 Earnings Call
Q3 2026 EARNINGS CALL NOVEMBER 6, 2026 Anika. Restore Active Living.
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS Cautionary Note on Forward-looking Statements The statements made in, and during the course of, this presentation that are not statements of historical fact, including those related to the Company’s commercial capabilities, initiatives and production, its product pipeline and
Slide 3: Company Highlights
COMPANY HIGHLIGHTS STRATEGY DRIVING GROWTH, OPERATIONAL DISCIPLINE AND PIPELINE ADVANCEMENT Growth Operational Discipline New Product Pipeline • Commercial Channel revenue increased • Gross margin of 62% vs 56% in the prior- • Hyalofast® PMA: received FDA not 17% year-over-year to $14.0M, driven by
Slide 4: Integrity Unit Sales Update
INTEGRITY UNIT SALES UPDATE Integrity Unit Sales Since Launch 700 2500 600 2000 500 1500 400 • Integrity revenue grew both sequentially and more than 30% 300 year-over-year in Q3 1000 • Year-to-date Integrity revenue up 37%, with $7.5M of trailing- 200 twelve-month revenue 500 100 • Larger sizes int
Slide 5: Q3 2026 Financial Highlights
Q3 2026 FINANCIAL HIGHLIGHTS 3Q26 Continuing Operations Highlights $M, except per share data CONTINUING OPERATIONS • Revenue of $30.6M increased 10% year-over-year (vs Q3 Financial Results 2026 VPY $27.8M), driven by growth in both the Commercial and OEM Channels Revenue $30.6 10% • Commercial Chann
Slide 6: 2026 and Long-Term Revenue Guidance
2026 AND LONG-TERM REVENUE GUIDANCE +6% to 0% to $121 $120 +10% Updates to Prior Guidance $114 +5% $113 $107 • Raising lower end of full year 2026 Revenue $95 total company revenue growth to +5% Flat to +6% to +10% (from 5%-10%) to Modestly 85 78 64 • Raising 2026 OEM growth to 5%-9% 82 +9% Lower (f
Slide 7: Strategies to Deliver Shareholder Value
3 STRATEGIES TO DELIVER SHAREHOLDER VALUE • Accelerating Growth driven by strong Commercial Channel momentum and OEM contributions • Strengthening Operational Discipline with improved productivity and disciplined expense control • Advancing a Robust New Product Pipeline with Hyalofast, Cingal, the I
Slide 8: Non-GAAP Reconciliation and Supplemental Data
NON-GAAP RECONCILIATION AND SUPPLEMENTAL DATA 8
Slide 9: Statement of Operations
STATEMENT OF OPERATIONS Anika Confidential 9
Slide 10: Balance Sheet
BALANCE SHEET Anika Confidential 10
Slide 11: Cash Flow Statement
CASH FLOW STATEMENT Anika Confidential 11
Slide 12: Reconciliation Tables – GAAP Net Income (Loss) to Adjusted EBITDA
RECONCILIATION TABLES – GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA Anika Confidential 12
Slide 13: Reconciliation Tables – GAAP Net Income to Adjusted Net Income
RECONCILIATION TABLES – GAAP NET INCOME TO ADJUSTED NET INCOME Anika Confidential 13
Slide 14: Reconciliation Tables – GAAP EPS to Adjusted EPS
RECONCILIATION TABLES – GAAP EPS TO ADJUSTED EPS Anika Confidential 14
Slide 15: Revenue by Channel
REVENUE BY CHANNEL Anika Confidential 15
Slide 16: @Anika
@ANIKA